The initiation of this human trial follows strong pre-clinical results revealing that INO-5150 generated healthy CD8+ T cell responses in animal studies including non-human primates. The company noted
Upon closing of the transaction, which has been unanimously approved by the Boards of Directors of both the companies, Allergan will receive $33.75bn in cash and Teva shares
Zerbaxa for injection (1.5g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium. The positive
Of the total amount, Allergan will pay $460m upon closing of the deal, while $100m will be paid by 2016. The deal will also include potential research and
As part of the deal, Knight will be responsible or handling all regulatory and commercial activities for AzaSite in Canada. AzaSite 1% is a prescription sterile eye drop
The drug is approved for adults with laBCC, which has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The
If Brinavess successfully completes the Phase I trial, which will be conducted in healthy volunteers, Eddingpharm intends to start a pivotal Phase III study by year end. Cardiome
The drug is approved for adults who require additional lowering of low-density lipoprotein (LDL) cholesterol. Praluent is the FDA-approved treatment in a new class of drugs known as
Following the positive opinion, the World Health Organization (WHO) will now formulate a policy recommendation on use of the vaccine in national immunization programs once approved by national
Technivie is an all-oral, interferon-free, direct-acting antiviral treatment consisting of the fixed-dose combination of paritaprevir/ritonavir (150/100mg) co-formulated with ombitasvir (25mg) dosed once daily and taken with a meal,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.